Synthetic organic

C108297.

C108297.

InformationC188-9 (TTI 101) is a potent inhibitor ofSTAT3that binds to STAT3 with high affinity (KD=4.7±0.4 nM). C188-9 is well tolerated in mice, shows good oral bioavailability, and is concentrated in tumors.TargetsSTAT3 (Cell-free) 4.7 nM(Kd)In

InformationC188-9 (TTI 101) is a potent inhibitor ofSTAT3that binds to STAT3 with high affinity (KD=4.7±0.4 nM). C188-9 is well tolerated in mice, shows good oral bioavailability, and is concentrated in tumors.TargetsSTAT3 (Cell-free) 4.7 nM(Kd)In

InformationC188-9 (TTI 101) is a potent inhibitor ofSTAT3that binds to STAT3 with high affinity (KD=4.7±0.4 nM). C188-9 is well tolerated in mice, shows good oral bioavailability, and is concentrated in tumors.TargetsSTAT3 (Cell-free) 4.7 nM(Kd)In

InformationC188-9 (TTI 101) is a potent inhibitor ofSTAT3that binds to STAT3 with high affinity (KD=4.7±0.4 nM). C188-9 is well tolerated in mice, shows good oral bioavailability, and is concentrated in tumors.TargetsSTAT3 (Cell-free) 4.7 nM(Kd)In

InformationC188-9 (TTI 101) is a potent inhibitor ofSTAT3that binds to STAT3 with high affinity (KD=4.7±0.4 nM). C188-9 is well tolerated in mice, shows good oral bioavailability, and is concentrated in tumors.TargetsSTAT3 (Cell-free) 4.7 nM(Kd)In

C₇/3-phth.

C₇/3-phth.

CAA0225 is an epoxysuccinyl peptide and highly selective rat liver cathepsin L inhibitor (IC|50|= 1.9 nM), while exhibiting little to no effect on rat liver cathepsin B at concentrations higher than 1000-5000 nM,|in vitro|. During autophagy, it has

CAA0225.

CAA0225.